ABSTRACT
OBJECTIVE: To investigate the short-term effect of recombinant human erythropoietin (EPO) on patients with severe traumatic brain injury. METHODS: One hundred and fifty-nine patients with severe traumatic brain injury were randomly divided into EPO (n=79) and control group (n=80). EPO group was treated with subcutaneous injection of EPO (100 units/kg) on day 1, 3, 6, 9 and 12 following the brain injury. Glasgow outcome scores (GOS) were used to evaluate the outcomes three months after the treatment. Serum neuron specific enolase (NSE) and S-100ß protein were measured within the first three months after treatment. RESULTS: In the end, 146 patients (75 of the EPO group and 71 of the control group) completed the trial. Three months after the treatment, Good recovery was found in 33.3% of the EPO and 12.6% of the control group patients (p<0.05). Serum NSE and S-100ß protein were decreased gradually in both groups after treatment, but their levels in the EPO group were lower than that of control group (p<0.05). There was no statistically significant difference in blood pressure, hemoglobin levels, pneumonia, sepsis or thromboembolic events between the two groups three months after the treatment (p>0.05). CONCLUSION: Treatment with five doses of recombinant human erythropoietin is associated with an improved functional recovery in patients with severe traumatic brain injury. This treatment does not seem to increase the risk of thromboembolic events or severe infections.
Subject(s)
Brain Injuries, Traumatic/drug therapy , Erythropoietin/pharmacology , Outcome Assessment, Health Care , Recovery of Function , Adult , Brain Injuries, Traumatic/blood , Double-Blind Method , Erythropoietin/administration & dosage , Female , Humans , Male , Middle Aged , Phosphopyruvate Hydratase/blood , Recombinant Proteins , S100 Calcium Binding Protein beta Subunit/bloodABSTRACT
BACKGROUND: This study was designed to assess the clinical effect of bone marrow mononuclear cells including mesenchymal stem cell (MSCs) in patients with intracerebral hemorrhage (ICH). METHODS: One hundred patients were divided into a study (n=60) or a control group (n=40). Bone marrow mononuclear cells from the same patient were injected to the perihemorrhage area in the base ganglia through an intracranial drainage tube 5.9 days after ICH. National Institute Stroke Scale (NIHSSS) and Barthel index was used to assess neurologic impairment and daily activities, respectively, before and 6 months after intervention. RESULTS: Six months after implantation, the NIHSS score in the study group was lower than in the control group (10.09 ± 8.86 vs 14.35 ± 10.14, P<0.01), whereas the Barthel scores were higher (57.39 ± 23.51 vs 46.90 ± 20.29, P<0.01). Neurological and functional improvement was observed in 52 (86.7%) of the study group patients, and in 17 (42.5%) of the control group patients (P=0.001). No allergic or other adverse effects were observed in the study group. CONCLUSION: Autologous bone marrow mononuclear cell implantation reduced neurological impairment and improved activities of daily living in a selected group of ICH patients. Further studies are required to ascertain the long-term safety and efficacy of this treatment.
Subject(s)
Bone Marrow Transplantation , Cerebral Hemorrhage/therapy , Stroke/therapy , Activities of Daily Living , Adult , Aged , Bone Marrow Cells/cytology , Bone Marrow Transplantation/methods , Cerebral Hemorrhage/physiopathology , Female , Humans , Male , Middle Aged , Prospective Studies , Stroke/physiopathology , Transplantation, Autologous/adverse effects , Transplantation, Autologous/methods , Treatment OutcomeABSTRACT
OBJECTIVE: To evaluate the efficacy and toxicity of combination therapy with surgery and recombinant adenovirus-p53 injection of recurrent malignant gliomas. METHODS: 38 patients with recurrent malignant gliomas were included in this study. Among them, 18 patients of combined treatment group had Ommaya reservoirs placed into the tumor cavities after the resection of the tumors and received regular recombinant adenovirus-p53 injections after the operation. The other 20 patients received surgery alone. RESULTS: The 6-month and 1-year survival rates after the combination therapy were 66.7% (14/18) and 44.4% (8/18), respectively. The median survival time was 9.7 months. Compared with the surgery-alone group, the combined treatment group achieved significant improvement (P < 0.05). The Karnofsky score was significantly improved at 6 months after the combination therapy compared with that before the treatment (P < 0.05). CONCLUSION: The recombinant adenovirus-p53 injection is safe and effective in treatment of recurrent malignant gliomas. The combination therapy of surgery and recombinant adenovirus-p53 injection may improve the life quality and the prognosis in patients with recurrent malignant gliomas.
Subject(s)
Brain Neoplasms/therapy , Genetic Therapy , Glioma/therapy , Recombinant Proteins/therapeutic use , Tumor Suppressor Protein p53/therapeutic use , Adenoviridae/genetics , Adult , Brain Neoplasms/pathology , Brain Neoplasms/surgery , Combined Modality Therapy , Female , Follow-Up Studies , Genes, p53 , Glioma/pathology , Glioma/surgery , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Survival Rate , Tumor Suppressor Protein p53/geneticsABSTRACT
OBJECTIVE: To evaluate the treatment results of stereotactic (186)Re intracavitary irradiation in the patients with craniopharyngioma. METHODS: Nineteen patients were treated with stereotactic (186)Re intracavitary irradiation, including 12 males and 7 females (average age, 37.2 years). Among them 12 patients had a solitary cyst, whereas 7 patients with mixed structure (e.g., a large cyst with a small solid portion). The mean volume of the cystic portion of the tumor before irradiation was 8390 mm(3). RESULTS: The patients were followed up for 6 months to 3 years. The retraction of the cyst was complete in 7 patients, cyst volume decreased more than 50% in 5 patients and less than 50% in 7 cases. Among the 8 patients with visual acuity deficit before irradiation, 5 were improved. No hypopituitarism occurred in patients with normal pituitary function before treatment. One of the 4 patients with hypopituitarism was improved, 3 of the 5 patients with diabetes insipidus was improved. CONCLUSION: Stereotactic (186)Re endocavitary irradiation for the treatment of cystic craniopharyngioma is a safe and effective procedure.
Subject(s)
Brachytherapy/methods , Craniopharyngioma/radiotherapy , Pituitary Neoplasms/radiotherapy , Radioisotopes/therapeutic use , Rhenium/therapeutic use , Adolescent , Adult , Child , Child, Preschool , Cysts/radiotherapy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Stereotaxic Techniques , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: To explore the effective methods for evaluating the consciousness and speech status of patients with special types of cerebral injuries. METHODS: A total of 96 patients with injury in the language center and in coma were treated with operative and correlated conventional therapies. Then their recovery status of consciousness and speech was observed. RESULTS: All the patients were recovered to consciousness. Sixty-nine patients with aphasia were cured completely, but 7 patients were complicated with incomplete ataxic aphasia, 15 with incomplete sensory aphasia, and 5 with incomplete mixed aphasia. CONCLUSIONS: For the patients with injury in the language center, evaluation of the conscious state with GCS scoring system has certain limitations and conscious behaviours are advantageous evidences to evaluate the consciousness recovery of the patients. The patients with conscious disturbance and injury in the language center should be considered to have aphasia.
